USANA Health Sciences, Inc. (NYSE:USNA) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totalling 1,907,700 shares, an increase of 28.3% from the May 30th total of 1,487,400 shares. Based on an average trading volume of 339,900 shares, the short-interest ratio is currently 5.6 days. Approximately 14.2% of the company’s stock are short sold.
Several research analysts have issued reports on the company. Sidoti lowered OMNOVA Solutions from a “buy” rating to a “neutral” rating and set a $10.00 price target on the stock. in a report on Wednesday, July 3rd. Pivotal Research reiterated a “buy” rating and issued a $75.00 price target on shares of USANA Health Sciences in a report on Wednesday, July 3rd. Tigress Financial assumed coverage on USANA Health Sciences in a report on Tuesday, April 16th. They issued a “buy” rating on the stock. TheStreet upgraded VEON from a “d+” rating to a “c-” rating in a report on Thursday. Finally, ValuEngine upgraded Westpac Banking from a “sell” rating to a “hold” rating in a report on Wednesday, May 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. USANA Health Sciences currently has a consensus rating of “Hold” and an average target price of $72.50.
USNA stock opened at $59.73 on Friday. USANA Health Sciences has a twelve month low of $58.30 and a twelve month high of $137.95. The firm has a 50 day moving average of $71.74. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of 12.12 and a beta of 0.51.
USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, April 30th. The company reported $1.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.02. USANA Health Sciences had a return on equity of 29.51% and a net margin of 10.38%. The company had revenue of $272.90 million for the quarter, compared to analyst estimates of $272.20 million. During the same quarter last year, the company earned $1.19 earnings per share. The company’s revenue for the quarter was down 6.5% on a year-over-year basis. Equities analysts predict that USANA Health Sciences will post 3.9 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the company. Citigroup Inc. lifted its holdings in shares of USANA Health Sciences by 20.0% in the first quarter. Citigroup Inc. now owns 30,271 shares of the company’s stock valued at $2,539,000 after purchasing an additional 5,047 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of USANA Health Sciences by 392.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 14,746 shares of the company’s stock valued at $1,955,000 after purchasing an additional 11,754 shares in the last quarter. NumerixS Investment Technologies Inc bought a new position in shares of USANA Health Sciences in the fourth quarter valued at approximately $34,000. Marshall Wace North America L.P. bought a new position in shares of USANA Health Sciences in the first quarter valued at approximately $1,305,000. Finally, SG Americas Securities LLC bought a new position in shares of USANA Health Sciences in the first quarter valued at approximately $193,000. Institutional investors own 59.70% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Featured Story: What kind of dividend yield to CEF’s pay?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.